EMRELIS (telisotuzumab vedotin-tllv)

TherapyAbbVie

EMRELIS (telisotuzumab vedotin-tllv) from AbbVie is an antibody-drug conjugate for biomarker-defined lung cancer populations.

Approvals

Indications

Biomarkers

Mapped tests

Where this therapy is approved with a companion diagnostic

Each row represents a defined combination of indication, biomarker criteria, and EMRELIS. Select a testing pathway to see the eligible companion diagnostic tests.

Indication-specific approvals

Approvals where EMRELIS is tied to a specific indication and biomarker definition.

Indication	Biomarker criteria	Notes
Non-Small Cell Lung Cancer (NSCLC) Solid Tumor · Lung	MET MET protein expression (>= 50% of tumor cells exhibiting strong membrane and/or cytoplasmic staining 3+)		View testing pathway →

Tumor-agnostic approvals

Approvals defined at the solid tumor level where biomarker criteria determine eligibility for EMRELIS.

No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.

Tests used in these approvals

These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering EMRELIS for eligible patients.

Test

Ventana MET (SP44) RxDx Assay

Ventana Medical Systems, Inc. (Roche Diagnostics)

Method

IHC

Specimen

Tissue (FFPE)

1 approvalView test profile →

This view is scoped to EMRELIS (telisotuzumab vedotin-tllv). You can also see how it compares with other therapies and indications on the main Know Your Companions™ map.